Merit Medical Systems

Merit Medical Systems, Inc. engages in the manufacture and marketing of proprietary disposable medical devices. It operates through the Cardiovascular and Endoscopy segments. The Cardiovascular segment consists of peripheral intervention, cardiac intervention, interventional oncology and spine, and cardiovascular and critical care product groups. The Endoscopy segment integrates non-vascular stent technology with balloon dilators, inflation devices, guide wires, procedure kits, and other devices that are used by gastroenterologists, endoscopists, pulmonologists, and thoracic and general surgeons. The company was founded by Fred P. Lampropoulos, Darla Gill, Kent W. Stanger, and William Padilla in July 1987 and is headquartered in South Jordan, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merit Medical Systems reports robust Q4 performance and eyes growth

Merit Medical Systems delivered a strong Q4 performance with revenue growth, increased gross profit, and exceeding net income expectations.
While facing challenges in certain segments and regulatory compliance, the company remains optimistic about growth opportunities and operational improvements.
Strategic pricing initiatives and a focus on achieving financial targets position Merit Medical for continued success and potential expansion through M&A activities.
The company's commitment to discipline, prioritization, and operational excellence underscores its resilience and potential for sustained growth in the future.

Merit Medical Systems posts strong Q1 results, eyes debt reduction

Merit Medical Systems delivered robust financial results in Q1 2023, showcasing growth in revenue, operating income, and net income. The company maintains its financial guidance for 2023, emphasizing a commitment to debt reduction and free cash flow targets. Analyst inquiries highlighted areas for improvement and strategic focus moving forward.

Merit Medical Systems reports robust Q2 earnings amidst strategic acquisitions

Merit Medical Systems delivered strong financial performance in Q2 2023, marked by revenue growth, improved profitability, and strategic acquisitions. While facing challenges in the Endoscopy segment and uncertainties in international markets, the company remains focused on leveraging opportunities in catch-up procedures and strategic M&A for sustainable growth.

Merit Medical Systems excels in Q3, eyes growth opportunities

Merit Medical Systems delivered a strong Q3 performance with notable revenue growth, profit increases, and enhanced net income and EPS.
While facing challenges like margin pressure and regional headwinds, the company remains focused on long-term growth strategies and operational efficiency.
With opportunities for revenue expansion, product advancements, and margin improvements on the horizon, Merit Medical Systems is poised for continued success and shareholder value creation.

Merit Medical Systems excels in Q4 2023, eyes strategic growth

Merit Medical Systems delivered strong financial results in Q4 2023, driven by revenue growth and margin expansion.
The company's strategic initiatives and focus on operational efficiency position it well for future growth and profitability.
Challenges such as SKU rationalization and China revenue decline require careful management and strategic planning.
Opportunities in M&A, pricing power initiatives, R&D investments, and gross margin expansion strategies offer avenues for continued success.

Merit Medical Systems excels in Q1, eyes growth opportunities

Merit Medical Systems delivered strong Q1 results with revenue growth and profitability improvements, driven by operational progress and strategic focus on innovation.
While facing challenges such as pricing pressures in China and debt reduction strategies, the company remains poised for growth through new opportunities and market strategies.
With a solid performance in Q1 and positive Q2 guidance, Merit Medical Systems demonstrates resilience and a strategic approach to navigating industry challenges.
The company's commitment to financial stability, innovation, and shareholder value sets a strong foundation for future growth and market competitiveness.

Merit Medical Systems reports robust Q3 results amidst supply challenges

Merit Medical Systems delivered strong financial results in Q3, driven by revenue growth and margin improvement.
The company's strategic acquisition and focus on innovation position it well for future growth despite supply chain disruptions.
Challenges in supply chain management and analyst inquiries highlight areas for ongoing attention and improvement.
Overall, Merit Medical Systems maintains a positive outlook on its performance and growth trajectory.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Henry Schein

West Pharmaceutical Services

Let's keep a watch on three lucrative stocks, WST, HSIC and MMSI, in the dental space that investors can add to their watchlist backed by robust long-term prospects.

3 Dental Stocks Poised to Perform Well in Second-Half 2021

Merit Medical (MMSI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Merit Medical (MMSI) Soars to 52-Week High, Time to Cash Out?

Merit Medical's (MMSI) new commercial product launch can make sample collection simple, safe and efficient.

Merit Medical (MMSI) Expands Drainage Portfolio With New Product

Advanced design makes sample collection simple, efficient, and safe Advanced design makes sample collection simple, efficient, and safe

Merit Medical Launches One-Vac™ Evacuated Drainage Bottle for Percutaneous Fluid Collection and Discard

Merit Medical (MMSI) Hits Fresh High: Is There Still Room to Run?

Merit Medical Systems, Inc. (MMSI) CEO Fred Lampropoulos on Q2 2021 Results - Earnings Call Transcript

Merit Medical (MMSI), in the second quarter, benefits from revenue growth across both its segments as well as across all the product categories within its Cardiovascular unit.

Merit Medical's (MMSI) Q2 Earnings Top Estimates, '21 View Up

* Constant currency revenue; constant currency revenue, organic; core revenue; non-GAAP EPS; non-GAAP net income; non-GAAP operating income and margin; non-GAAP gross margin; and free cash flow are non-GAAP financial measures. A reconciliation of these financial measures to their most directly comparable GAAP financial measures is included under the heading “Non-GAAP Financial Measures” below.

Merit Medical Reports Results for Quarter Ended June 30, 2021

Merit Medical (MMSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Merit Medical (MMSI) Reports Next Week: Wall Street Expects Earnings Growth

SOUTH JORDAN, Utah, July 09, 2021 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, announced today that it will release its financial results for the quarter ended June 30, 2021, after the close of the stock market on Thursday, July 29, 2021.

Merit Medical Systems to Announce Second Quarter Results on July 29, 2021

Becton, Dickinson and Co.

Boston Scientific

Edwards Lifesciences

Medtronic

These cardiology device stocks Medtronic (MDT), Boston Scientific (BSX), Edwards Lifesciences (EW), Merit Medical (MMSI), BD (BDX) are expected to continue their run over the next few months.

Cardiology Space Gains Momentum in 2021: 5 Stocks to Focus on

Merit Medical Systems, Inc. (MMSI) CEO Fred Lampropoulos on Q1 2021 Results - Earnings Call Transcript

Merit Medical (MMSI) benefits from growth in revenues at the Cardiovascular segment in Q1.

Merit Medical (MMSI) Q1 Earnings and Revenues Beat Estimates

Shares of Merit Medical Systems (NASDAQ:MMSI) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 36.84% year over year to $0.52, which beat the estimate of $0.36.

Merit Medical Systems: Q1 Earnings Insights

*  Constant currency revenue; constant currency revenue, organic; core revenue; non-GAAP EPS; non-GAAP net income; non-GAAP operating income and margin; non-GAAP gross margin; and free cash flow are non-GAAP financial measures. A reconciliation of these and other non-GAAP financial measures used in this release to their most directly comparable GAAP financial measures is included under the heading “Non-GAAP Financial Measures” below.

Merit Medical Reports Results for Quarter Ended March 31, 2021

Merit Medical Systems (NASDAQ:MMSI) releases its next round of earnings this Thursday, April 29. Get the latest predictions in Benzinga's essential guide to the company's Q1 earnings report.

Merit Medical Systems Earnings Preview

Earnings Preview: Merit Medical (MMSI) Q1 Earnings Expected to Decline

McKesson

DENTSPLY SIRONA

Let's keep a watch on three lucrative stocks, XRAY, MCK and MMSI, in the dental space that have performed impressively despite the pandemic-led volatility.

Dental Market Shows Strength Despite Pandemic: 3 Stocks to Watch

LOS ANGELES--(BUSINESS WIRE)---- $MMSI #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announces that it has commenced an investigation of potential claims against the board of directors of Merit Medical Systems, Inc. (“Merit Medical” or the “Company) (NASDAQ: MMSI) concerning whether the board of directors breached its fiduciary duties to Merit Medical shareholders. If you still hold Merit Medical shares purchased before February 2019 and wish to discuss t

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Merit Medical Systems, Inc. (MMSI) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)---- $MMSI #investors--The Law Offices of Frank R. Cruz Announces Investigation of Merit Medical Systems, Inc. (MMSI) on Behalf of Investors

The Law Offices of Frank R. Cruz Announces Investigation of Merit Medical Systems, Inc. (MMSI) on Behalf of Investors

NEW YORK--(BUSINESS WIRE)---- $MMSI--The law firm of Kirby McInerney LLP is investigating claims against Merit Medical Systems, Inc. (“Merit Medical” or the “Company”) (NASDAQ: MMSI). The investigation focuses on whether the Company's board of directors has breached its fiduciary duties to the Company. If you purchased or otherwise acquired Merit Medical securities, have information, or would like to learn more about these claims, please contact Thomas W. Elrod of Kirby McInerney LLP at 212-371-6600, by

INVESTOR ALERT: Kirby McInerney LLP Continues Investigation of Shareholder Claims Against Merit Medical Systems, Inc.

SAN FRANCISCO, April 12, 2021 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP is investigating potential derivative claims on behalf of shareholders of Merit Medical Systems, Inc. (NASDAQ: MMSI) relating to possible false statements to investors and insider trading by officers and directors.  A securities class action against the company in the United States District Court for the Central District of California recently survived a motion to dismiss allegations that between February 26 and October 30, 2019, Merit and its CEO and CFO made false and misleading statements about the company's integration of Cianna and ClariVein, two highly-touted corporate acquisitions.

SHAREHOLDER ALERT: Merit Medical Systems, Inc. (MMSI) Officers and Directors Under Investigation for False Statements and Insider Trading

INVESTOR ALERT: Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against Merit Medical Systems, Inc.

SOUTH JORDAN, Utah, April 09, 2021 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, announced today that it will release its financial results for the first quarter ended March 31, 2021, after the close of the stock market on Thursday, April 29, 2021.

Merit Medical Systems to Announce First Quarter Results on April 29, 2021

SOUTH JORDAN, Utah, April 08, 2021 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, announced today that it will participate in an upcoming investor conference.

News for Merit Medical Systems Stock (MMSI)